<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003104</url>
  </required_header>
  <id_info>
    <org_study_id>97-064</org_study_id>
    <secondary_id>CDR0000065838</secondary_id>
    <secondary_id>NCI-H97-0006</secondary_id>
    <nct_id>NCT00003104</nct_id>
  </id_info>
  <brief_title>Computer Planned Radiation Therapy in Treating Patients With Prostate Cancer</brief_title>
  <official_title>A Phase II Study Using High Dose Three Dimensional Conformal Radiation Therapy in Intermediate Prognostic Risk Patients With Adenocarcinoma of the Prostate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Computer systems&#xD;
      that allow doctors to create a 3-dimensional picture of the tumor in order to plan treatment&#xD;
      may result in more effective radiation therapy.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well radiation therapy that has been planned&#xD;
      with a computer works in treating patients with prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Establish the efficacy of high-dose three-dimensional conformal radiotherapy in patients&#xD;
           with intermediate prognostic risk adenocarcinoma of the prostate.&#xD;
&#xD;
        -  Determine the PSA relapse-free survival rate of this patient population.&#xD;
&#xD;
      OUTLINE: Patients receive high-dose three-dimensional conformal radiotherapy 4-5 days per&#xD;
      week for at least 9 weeks.&#xD;
&#xD;
      Patients are evaluated at least weekly during radiotherapy and at 2 and 4 months after&#xD;
      treatment completion. Thereafter, patients are followed every 6 months for a total of 3&#xD;
      years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1997</start_date>
  <completion_date type="Actual">October 2005</completion_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven intermediate prognostic risk (T1-T2) adenocarcinoma of the&#xD;
             prostate&#xD;
&#xD;
               -  Previously untreated (except for hormonal therapy)&#xD;
&#xD;
               -  PSA levels greater than 10 ng/mL and Gleason scores no greater than 6 OR&#xD;
&#xD;
               -  PSA levels no greater than 10 ng/mL and Gleason scores at least 7&#xD;
&#xD;
               -  Patients requiring volume reduction of prostate prior to radiotherapy continue to&#xD;
                  be treated at least 3 months on neoadjuvant hormonal therapy prior to radiation&#xD;
&#xD;
          -  No evidence of distant metastases&#xD;
&#xD;
          -  No regional lymph node involvement&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No major medical illness&#xD;
&#xD;
          -  No psychosis&#xD;
&#xD;
          -  No metallic pelvic prosthesis&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior neoadjuvant antiandrogen therapy allowed&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiotherapy&#xD;
&#xD;
          -  No prior pelvic irradiation&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  No prior radical surgery for carcinoma of the prostate&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael J. Zelefsky, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 24, 2013</last_update_submitted>
  <last_update_submitted_qc>June 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2013</last_update_posted>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage IIB prostate cancer</keyword>
  <keyword>stage IIA prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

